Last reviewed · How we verify

NCT03452163

Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit

Terminated NA Last updated 6 May 2021
What this trial tests

NA trial testing PMD-200 in Anesthesia, General in 3 participants. Terminated before completion.

Timeline
8 March 2018
Primary endpoint
30 November 2019
30 November 2019

Quick facts

Lead sponsorMedasense Biometrics Ltd
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment3
Start date8 March 2018
Primary completion30 November 2019
Estimated completion30 November 2019
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Medasense Biometrics Ltd — full company profile →

Who can join

Adults 18 to 100, any sex, with Anesthesia, General. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Performance Assessment of the PMD-200, a Novel Pain Monitor, in Subjects at Neurointensive Care Unit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PMD-200

Trials testing the same drug.

Other recruiting trials for Anesthesia, General

Currently open trials in the same condition.

Other Medasense Biometrics Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03452163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing